Moderna Stock News

Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.

Moderna stock (NASDAQ: MRNA) rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking funds. The move follows a spectacular 2026 rally that has pushed Moderna more than 500% higher and transformed it from a post-pandemic recovery story into an oncology bet.

Nike slumps after the retailer misses analysts' first-quarter earnings target and issues downbeat full-year guidance.

Nasdaq ​said on Thursday ‌that vaccine maker Moderna will replace Warner ​Bros. Discovery on ​the Nasdaq 100 index , ⁠effective October 9.

With potential profit-taking on the horizon, it could mean Moderna's upside is limited in the short-term.

Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight?

Moderna's stock has been flying high lately. That has one group of analysts saying it's time to sell.

Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.